KEY POINTS
- Incyte’s oral JAK1 inhibitor, povorcitinib, demonstrated significant and sustained symptom relief for patients with moderate-to-severe hidradenitis suppurativa over 52 weeks.
- Data from the Phase 3 trials revealed that a majority of participants maintained a 50% or greater reduction in abscesses and inflammatory nodules through the one-year mark.
- The treatment remained well-tolerated throughout the extended study period, with no new or unexpected safety concerns identified among the patient cohort.
Incyte has released encouraging long-term results from its Phase 3 clinical program evaluating povorcitinib, an investigational oral JAK1 inhibitor, for the treatment of hidradenitis suppurativa (HS). The 52-week data, presented at a major dermatological congress, highlights the drug’s ability to provide durable relief for a chronic and often debilitating inflammatory skin condition. HS is characterized by painful, recurring lumps and abscesses, and these latest findings suggest that povorcitinib could offer a much-needed systemic alternative to existing therapies.
The clinical trials, known as POMPEII-1 and POMPEII-2, met their primary objectives early on, but the new one-year data focuses on the consistency of the patient response. Researchers found that patients who initially responded to the once-daily oral medication continued to see improvements in their skin condition over time. A substantial percentage of participants achieved a Hidradenitis Suppurativa Clinical Response (HiSCR50), meaning they experienced at least a 50% reduction in total abscess and inflammatory nodule count without an increase in abscesses or draining tunnels.
One of the most promising aspects of the long-term data is the depth of the response. Beyond the standard 50% improvement metric, a significant portion of the study population achieved higher levels of clearance, such as HiSCR75 and even HiSCR90. This indicates that for many patients, the medication can lead to a near-total resolution of active inflammatory lesions. Given that HS is notoriously difficult to manage and often requires a combination of surgery and long-term antibiotics, a highly effective oral pill represents a major shift in the treatment landscape.
The safety profile of povorcitinib remained consistent with earlier reports and the broader class of JAK inhibitors. Over the course of the 52-week extension, the most common side effects included upper respiratory tract infections, headaches, and acne. Importantly, the researchers noted that there were no significant spikes in serious adverse events or opportunistic infections, which are often a concern with immune-modulating therapies. This stability in safety is crucial for a medication intended for the lifelong management of a chronic disease.
Incyte’s leadership emphasized that these results underscore the potential of povorcitinib to address the high unmet need in the HS community. Many patients currently rely on biologic injections, which can be inconvenient or lose effectiveness over time. The company believes that providing an oral option with a fast-acting and sustained response could improve patient adherence and overall quality of life. The data also showed improvements in patient-reported outcomes, including a reduction in skin pain and a decrease in the systemic impact of the disease on daily activities.
Following the success of these late-stage trials, Incyte is moving forward with global regulatory submissions. If approved, povorcitinib would join a growing portfolio of JAK inhibitors targeting various dermatological and inflammatory conditions. The company plans to continue monitoring the long-term effects of the drug in ongoing extension studies to further solidify its safety and efficacy profile. For the millions of people worldwide living with the physical and psychological burden of HS, this data offers a path toward more predictable and manageable long-term health.
